While intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs have greatly improved the visual outcome of wet AMD (Brynskov et al., 2020), there is no treatment for dry AMD, which affects most patients. The gene discussed is VEGFA; the disease is wet macular degeneration.